Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD22 as a target of passive immunotherapy.
Cesano A, Gayko U. Cesano A, et al. Semin Oncol. 2003 Apr;30(2):253-7. doi: 10.1053/sonc.2003.50057. Semin Oncol. 2003. PMID: 12720147 Review.
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM. Leonard JP, et al. Among authors: cesano a. Clin Cancer Res. 2004 Aug 15;10(16):5327-34. doi: 10.1158/1078-0432.CCR-04-0294. Clin Cancer Res. 2004. PMID: 15328168 Clinical Trial.
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, Meshinchi S. Lacayo NJ, et al. Among authors: cesano a. Br J Haematol. 2013 Jul;162(2):250-62. doi: 10.1111/bjh.12370. Epub 2013 May 20. Br J Haematol. 2013. PMID: 23682827 Free PMC article. Clinical Trial.
Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, Paietta E, Tallman MS, Cripe LD, Atwater S, Appelbaum FR, Radich JP. Cesano A, et al. PLoS One. 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485. eCollection 2015. PLoS One. 2015. PMID: 25884949 Free PMC article.
131 results